NASDAQ:APEN - Apollo Endosurgery Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.75 +0.11 (+1.66 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$6.64
Today's Range$6.51 - $6.79
52-Week Range$3.55 - $8.50
Volume14,700 shs
Average Volume32,842 shs
Market Capitalization$114.51 million
P/E Ratio-3.35
Dividend YieldN/A
Beta0.34

About Apollo Endosurgery (NASDAQ:APEN)

Apollo Endosurgery logoApollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive APEN News and Ratings via Email

Sign-up to receive the latest news and ratings for APEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APEN
CUSIPN/A
Phone512-279-5100

Debt

Debt-to-Equity Ratio0.79
Current Ratio1.98
Quick Ratio1.38

Price-To-Earnings

Trailing P/E Ratio-3.35
Forward P/E Ratio-4.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$64.31 million
Price / Sales1.84
Cash FlowN/A
Price / CashN/A
Book Value$2.89 per share
Price / Book2.34

Profitability

EPS (Most Recent Fiscal Year)($2.01)
Net Income$-27,290,000.00
Net Margins-41.50%
Return on Equity-61.61%
Return on Assets-26.55%

Miscellaneous

Employees213
Outstanding Shares17,510,000

Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery (NASDAQ:APEN) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.07. The biotechnology company earned $15.74 million during the quarter, compared to analyst estimates of $16 million. Apollo Endosurgery had a negative net margin of 41.50% and a negative return on equity of 61.61%. View Apollo Endosurgery's Earnings History.

What price target have analysts set for APEN?

4 analysts have issued 12-month price objectives for Apollo Endosurgery's shares. Their forecasts range from $8.00 to $12.00. On average, they anticipate Apollo Endosurgery's stock price to reach $10.25 in the next year. View Analyst Ratings for Apollo Endosurgery.

What are Wall Street analysts saying about Apollo Endosurgery stock?

Here are some recent quotes from research analysts about Apollo Endosurgery stock:
  • 1. According to Zacks Investment Research, "Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. " (5/2/2018)
  • 2. Northland Securities analysts commented, "We note that the ASMBS Statement is not a guarantee of reimbursement for Orbera." (2/8/2018)

Who are some of Apollo Endosurgery's key competitors?

Who are Apollo Endosurgery's key executives?

Apollo Endosurgery's management team includes the folowing people:
  • Mr. Todd Newton, CEO & Director (Age 55)
  • Mr. Charles Tribié, Exec. VP of Operations (Age 65)
  • Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
  • Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
  • Dr. Robert Hawes M.D., Co-Founder and Innovation Partner

Has Apollo Endosurgery been receiving favorable news coverage?

Media coverage about APEN stock has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.24 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.85 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Apollo Endosurgery's major shareholders?

Apollo Endosurgery's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (1.89%), NJ State Employees Deferred Compensation Plan (0.90%), University of Texas Texas AM Investment Managment Co. (0.68%) and Dimensional Fund Advisors LP (0.35%). Company insiders that own Apollo Endosurgery stock include A/S Novo, Bret Schwartzhoff, Holdings A/S Novo, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Institutional Ownership Trends for Apollo Endosurgery.

Which major investors are selling Apollo Endosurgery stock?

APEN stock was sold by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co.. View Insider Buying and Selling for Apollo Endosurgery.

Which major investors are buying Apollo Endosurgery stock?

APEN stock was bought by a variety of institutional investors in the last quarter, including NJ State Employees Deferred Compensation Plan, Dimensional Fund Advisors LP and Russell Investments Group Ltd.. Company insiders that have bought Apollo Endosurgery stock in the last two years include Bret Schwartzhoff, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP, Todd Newton and William D Jr Mcclellan. View Insider Buying and Selling for Apollo Endosurgery.

How do I buy shares of Apollo Endosurgery?

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $6.75.

How big of a company is Apollo Endosurgery?

Apollo Endosurgery has a market capitalization of $114.51 million and generates $64.31 million in revenue each year. The biotechnology company earns $-27,290,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Apollo Endosurgery employs 213 workers across the globe.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]


MarketBeat Community Rating for Apollo Endosurgery (APEN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  193
MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Apollo Endosurgery (NASDAQ:APEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Apollo Endosurgery in the last 12 months. Their average twelve-month price target is $10.25, suggesting that the stock has a possible upside of 51.85%. The high price target for APEN is $12.00 and the low price target for APEN is $8.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.25$10.25$11.00$11.00
Price Target Upside: 51.85% upside75.21% upside79.74% upside157.09% upside

Apollo Endosurgery (NASDAQ:APEN) Consensus Price Target History

Price Target History for Apollo Endosurgery (NASDAQ:APEN)

Apollo Endosurgery (NASDAQ:APEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Piper Jaffray CompaniesInitiated CoverageOverweight$8.00MediumView Rating Details
2/8/2018Northland SecuritiesReiterated RatingBuy$12.00LowView Rating Details
1/4/2018Roth CapitalSet Price TargetBuy ➝ Buy$10.00HighView Rating Details
7/24/2017Craig HallumInitiated CoverageBuy$11.00HighView Rating Details
8/19/2016S&P Equity ResearchLower Price Target$3.15 ➝ $2.45N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Apollo Endosurgery (NASDAQ:APEN) Earnings History and Estimates Chart

Earnings by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Apollo Endosurgery (NASDAQ:APEN) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.6 EPS
Next Year EPS Consensus Estimate: $-1.1 EPS

Apollo Endosurgery (NASDAQ APEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018Q1 2018($0.40)($0.47)$16.00 million$15.74 millionViewN/AView Earnings Details
3/1/2018Q4 2017($0.34)($0.42)$16.64 million$16.14 millionViewN/AView Earnings Details
10/26/2017Q3 2017($0.39)($0.32)$16.72 million$16.54 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.24)($0.6410)$17.14 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.77)$14.62 millionViewN/AView Earnings Details
3/8/2017Q4 2016($35.01)$15.39 millionViewN/AView Earnings Details
8/9/2016Q2 2016($6.11)$0.01 millionViewN/AView Earnings Details
5/10/2016Q1 2016($4.62)$0.01 millionViewN/AView Earnings Details
3/22/2016Q4 2015($4.62)$0.01 millionViewN/AView Earnings Details
11/12/2015Q3 2015($6.16)$0.02 millionViewN/AView Earnings Details
5/8/2015Q1 2015($10.79)$0.78 millionViewN/AView Earnings Details
3/24/2015Q4 2014($26.19)$0.92 millionViewN/AView Earnings Details
11/12/2014Q3 2014($15.41)$1.11 millionViewN/AView Earnings Details
8/8/2014Q2 2014($20.80)$1.33 millionViewN/AView Earnings Details
5/9/2014Q1 2014($17.72)$1.72 millionViewN/AView Earnings Details
5/14/2012Q1 2012($10.78)($9.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Apollo Endosurgery (NASDAQ:APEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Apollo Endosurgery (NASDAQ APEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 52.80%
Institutional Ownership Percentage: 32.77%
Insider Trading History for Apollo Endosurgery (NASDAQ:APEN)
Institutional Ownership by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Apollo Endosurgery (NASDAQ APEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2018Matthew S CrawfordDirectorBuy4,038$6.20$25,035.6053,715View SEC Filing  
1/3/2018Stonepine Capital, L.P.Major ShareholderBuy22,845$5.71$130,444.952,560,314View SEC Filing  
12/29/2017Stonepine Capital, L.P.Major ShareholderBuy5,163$5.56$28,706.282,560,314View SEC Filing  
12/26/2017Stonepine Capital, L.P.Major ShareholderBuy5,287$5.00$26,435.002,555,151View SEC Filing  
12/22/2017Stonepine Capital, L.P.Major ShareholderBuy185,157$4.85$898,011.452,410,141View SEC Filing  
12/20/2017Stonepine Capital, L.P.Major ShareholderBuy45,434$4.50$204,453.002,410,141View SEC Filing  
11/7/2017Bret SchwartzhoffVPBuy9,500$4.24$40,280.0015,631View SEC Filing  
7/26/2017Holdings A/S NovoMajor ShareholderSell50,130$6.90$345,897.001,334,772View SEC Filing  
7/25/2017Richard J MeeliaDirectorBuy45,454$5.50$249,997.005,098View SEC Filing  
7/25/2017Sciences L P Ptv IIMajor ShareholderBuy1,090,909$5.50$5,999,999.50View SEC Filing  
7/25/2017Stefanie L CavanaughCFOBuy4,545$5.50$24,997.509,166View SEC Filing  
7/25/2017Todd NewtonCEOBuy136,363$5.50$749,996.50167,129View SEC Filing  
5/18/2017Todd NewtonCEOBuy2,121$6.22$13,192.6229,544View SEC Filing  
5/17/2017William D Jr. McclellanDirectorBuy2,000$6.33$12,660.00View SEC Filing  
5/11/2017A/S NovoMajor ShareholderSell105,000$5.63$591,150.001,455,472View SEC Filing  
12/12/2014Daniel H PetreeDirectorBuy10,000$2.79$27,900.00View SEC Filing  
8/20/2014Gary J G AtkinsonCFOBuy5,000$3.10$15,500.00View SEC Filing  
8/19/2014Scott R PancoastCEOBuy10,000$3.00$30,000.00View SEC Filing  
8/18/2014Scott R PancoastCEOBuy10,000$3.22$32,200.00View SEC Filing  
12/19/2012Charles MathewsDirectorBuy5,000$4.98$24,900.00View SEC Filing  
12/18/2012Scott R PancoastCEOBuy5,000$4.95$24,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Apollo Endosurgery (NASDAQ APEN) News Headlines

Source:
DateHeadline
Financial Survey: Apollo Endosurgery (APEN) versus Cerus (CERS)Financial Survey: Apollo Endosurgery (APEN) versus Cerus (CERS)
www.americanbankingnews.com - May 21 at 7:14 PM
 Brokerages Expect Apollo Endosurgery (APEN) Will Announce Quarterly Sales of $17.08 Million Brokerages Expect Apollo Endosurgery (APEN) Will Announce Quarterly Sales of $17.08 Million
www.americanbankingnews.com - May 15 at 4:26 AM
-$0.43 Earnings Per Share Expected for Apollo Endosurgery (APEN) This Quarter-$0.43 Earnings Per Share Expected for Apollo Endosurgery (APEN) This Quarter
www.americanbankingnews.com - May 13 at 5:20 AM
Critical Comparison: Apollo Endosurgery (APEN) vs. Its RivalsCritical Comparison: Apollo Endosurgery (APEN) vs. Its Rivals
www.americanbankingnews.com - May 9 at 11:26 AM
Apollo Endosurgery Establishes European Registry for Bariatric Flexible Endoscopic Suturing ProceduresApollo Endosurgery Establishes European Registry for Bariatric Flexible Endoscopic Suturing Procedures
finance.yahoo.com - May 8 at 4:19 PM
Apollo Endosurgery (APEN) Receives Consensus Recommendation of "Buy" from BrokeragesApollo Endosurgery (APEN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 8 at 3:18 AM
Apollo Endosurgery (APEN) Upgraded by ValuEngine to HoldApollo Endosurgery (APEN) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - May 7 at 11:10 PM
Apollo Endosurgery (APEN) Issues  Earnings ResultsApollo Endosurgery (APEN) Issues Earnings Results
www.americanbankingnews.com - May 4 at 4:36 PM
Apollo Endosurgery misses by $0.07, misses on revenueApollo Endosurgery misses by $0.07, misses on revenue
seekingalpha.com - May 4 at 9:32 AM
Critical Comparison: Apollo Endosurgery (APEN) versus Its CompetitorsCritical Comparison: Apollo Endosurgery (APEN) versus Its Competitors
www.americanbankingnews.com - May 3 at 8:36 PM
Apollo Endosurgery, Inc. Reports First Quarter 2018 ResultsApollo Endosurgery, Inc. Reports First Quarter 2018 Results
finance.yahoo.com - May 3 at 4:16 PM
Apollo Endosurgery (APEN) Set to Announce Earnings on ThursdayApollo Endosurgery (APEN) Set to Announce Earnings on Thursday
www.americanbankingnews.com - May 2 at 8:10 PM
Apollo Endosurgery (APEN) Lifted to Hold at Zacks Investment ResearchApollo Endosurgery (APEN) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - May 2 at 4:52 PM
Financial Analysis: Apollo Endosurgery (APEN) versus ATRION (ATRI)Financial Analysis: Apollo Endosurgery (APEN) versus ATRION (ATRI)
www.americanbankingnews.com - May 2 at 11:38 AM
Critical Analysis: Obalon Therapeutics (OBLN) & Apollo Endosurgery (APEN)Critical Analysis: Obalon Therapeutics (OBLN) & Apollo Endosurgery (APEN)
www.americanbankingnews.com - April 29 at 5:25 PM
Apollo Endosurgery (APEN) Expected to Post Quarterly Sales of $16.00 MillionApollo Endosurgery (APEN) Expected to Post Quarterly Sales of $16.00 Million
www.americanbankingnews.com - April 27 at 2:20 AM
Apollo Endosurgery, Inc. to Report First Quarter Results on May 3, 2018Apollo Endosurgery, Inc. to Report First Quarter Results on May 3, 2018
finance.yahoo.com - April 26 at 4:20 PM
Apollo Endosurgery (APEN) Expected to Post Earnings of -$0.40 Per ShareApollo Endosurgery (APEN) Expected to Post Earnings of -$0.40 Per Share
www.americanbankingnews.com - April 25 at 7:18 PM
Endologix (ELGX) versus Apollo Endosurgery (APEN) Head-To-Head ComparisonEndologix (ELGX) versus Apollo Endosurgery (APEN) Head-To-Head Comparison
www.americanbankingnews.com - April 24 at 7:58 PM
Apollos ORBERA365 OKd in Saudi ArabiaApollo's ORBERA365 OK'd in Saudi Arabia
seekingalpha.com - April 23 at 4:17 PM
Apollo Endosurgery Announces Approval of the New 12-month Weight Loss Balloon - ORBERA365™ - in the Kingdom of Saudi ArabiaApollo Endosurgery Announces Approval of the New 12-month Weight Loss Balloon - ORBERA365™ - in the Kingdom of Saudi Arabia
finance.yahoo.com - April 23 at 4:17 PM
Apollo Endosurgery (APEN) Receives New Coverage from Analysts at Roth CapitalApollo Endosurgery (APEN) Receives New Coverage from Analysts at Roth Capital
www.americanbankingnews.com - April 14 at 10:19 AM
Comparing Apollo Endosurgery (APEN) and The CompetitionComparing Apollo Endosurgery (APEN) and The Competition
www.americanbankingnews.com - April 14 at 3:17 AM
Financial Contrast: Apollo Endosurgery (APEN) vs. Its RivalsFinancial Contrast: Apollo Endosurgery (APEN) vs. Its Rivals
www.americanbankingnews.com - April 13 at 9:19 PM
Apollo Endosurgery (APEN) Downgraded by ValuEngine to "Strong Sell"Apollo Endosurgery (APEN) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - April 13 at 2:49 PM
Apollo Endosurgery (APEN) Earns Overweight Rating from Analysts at Piper JaffrayApollo Endosurgery (APEN) Earns Overweight Rating from Analysts at Piper Jaffray
www.americanbankingnews.com - April 13 at 10:37 AM
Apollo Endosurgery (APEN) Given Average Recommendation of "Hold" by AnalystsApollo Endosurgery (APEN) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 13 at 9:31 AM
Apollo Endosurgery (APEN) Expected to Announce Quarterly Sales of $16.00 MillionApollo Endosurgery (APEN) Expected to Announce Quarterly Sales of $16.00 Million
www.americanbankingnews.com - April 10 at 2:21 AM
-$0.38 EPS Expected for Apollo Endosurgery (APEN) This Quarter-$0.38 EPS Expected for Apollo Endosurgery (APEN) This Quarter
www.americanbankingnews.com - April 8 at 7:10 PM
Zacks: Apollo Endosurgery Inc (APEN) Given $10.83 Consensus Price Target by AnalystsZacks: Apollo Endosurgery Inc (APEN) Given $10.83 Consensus Price Target by Analysts
www.americanbankingnews.com - March 31 at 3:18 PM
Apollo Endosurgery (APEN) Stock Rating Upgraded by ValuEngineApollo Endosurgery (APEN) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 31 at 1:04 PM
Apollo Endosurgery Inc (APEN) Expected to Post Quarterly Sales of $16.00 MillionApollo Endosurgery Inc (APEN) Expected to Post Quarterly Sales of $16.00 Million
www.americanbankingnews.com - March 24 at 7:44 AM
 Brokerages Anticipate Apollo Endosurgery Inc (APEN) Will Post Earnings of -$0.39 Per Share Brokerages Anticipate Apollo Endosurgery Inc (APEN) Will Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - March 22 at 7:10 PM
Apollo Endosurgery (APEN) and Utah Medical Products (UTMD) Critical ContrastApollo Endosurgery (APEN) and Utah Medical Products (UTMD) Critical Contrast
www.americanbankingnews.com - March 22 at 3:10 AM
Apollo Endosurgery Announces Conclusion of LAP-BAND® Low BMI Post-Approval StudyApollo Endosurgery Announces Conclusion of LAP-BAND® Low BMI Post-Approval Study
finance.yahoo.com - March 20 at 9:52 AM
Apollo Endosurgery Inc (APEN) Director Matthew S. Crawford Acquires 4,038 SharesApollo Endosurgery Inc (APEN) Director Matthew S. Crawford Acquires 4,038 Shares
www.americanbankingnews.com - March 13 at 8:52 PM
Apollo Endosurgery (APEN) Stock Rating Lowered by Zacks Investment ResearchApollo Endosurgery (APEN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 6 at 4:42 PM
Stonepine Capital Management LLC Has $14.34 Million Holdings in Apollo Endosurgery Inc (APEN)Stonepine Capital Management LLC Has $14.34 Million Holdings in Apollo Endosurgery Inc (APEN)
www.americanbankingnews.com - March 6 at 2:53 PM
 Analysts Expect Apollo Endosurgery Inc (APEN) Will Announce Earnings of -$0.34 Per Share Analysts Expect Apollo Endosurgery Inc (APEN) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - March 5 at 3:10 PM
 Analysts Set $10.83 Target Price for Apollo Endosurgery Inc (APEN) Analysts Set $10.83 Target Price for Apollo Endosurgery Inc (APEN)
www.americanbankingnews.com - March 2 at 11:22 PM
Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2017 ResultsApollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - March 1 at 4:40 PM
Apollo Endosurgery (APEN) Endosurgery Announces First ORBERA U.S. Post-Approval PublicationApollo Endosurgery (APEN) Endosurgery Announces First ORBERA U.S. Post-Approval Publication
www.streetinsider.com - February 27 at 4:53 PM
Apollo Endosurgery Announces First ORBERA® U.S. Post-Approval PublicationApollo Endosurgery Announces First ORBERA® U.S. Post-Approval Publication
finance.yahoo.com - February 27 at 9:41 AM
BRIEF-Apollo Endosurgery Announces MFDS Approval For Orbera Intragastric Balloon SystemBRIEF-Apollo Endosurgery Announces MFDS Approval For Orbera Intragastric Balloon System
www.reuters.com - February 23 at 9:35 AM
Apollo Endosurgery Announces MFDS Approval for the ORBERA® Intragastric Balloon System in South Korea, a Non-Surgical Solution to Assist Patients with Weight LossApollo Endosurgery Announces MFDS Approval for the ORBERA® Intragastric Balloon System in South Korea, a Non-Surgical Solution to Assist Patients with Weight Loss
finance.yahoo.com - February 22 at 4:42 PM
Apollo Endosurgery, Inc. to Report Fourth Quarter and Full Year 2017 Results on March 1, 2018Apollo Endosurgery, Inc. to Report Fourth Quarter and Full Year 2017 Results on March 1, 2018
finance.yahoo.com - February 22 at 9:27 AM
Zacks: Brokerages Anticipate Apollo Endosurgery Inc (APEN) Will Announce Quarterly Sales of $16.64 MillionZacks: Brokerages Anticipate Apollo Endosurgery Inc (APEN) Will Announce Quarterly Sales of $16.64 Million
www.americanbankingnews.com - February 18 at 1:46 AM
-$0.34 EPS Expected for Apollo Endosurgery Inc (APEN) This Quarter-$0.34 EPS Expected for Apollo Endosurgery Inc (APEN) This Quarter
www.americanbankingnews.com - February 16 at 11:08 PM
Northland Securities Reaffirms "Buy" Rating for Apollo Endosurgery (APEN)Northland Securities Reaffirms "Buy" Rating for Apollo Endosurgery (APEN)
www.americanbankingnews.com - February 8 at 11:18 AM
Zacks: Analysts Anticipate Apollo Endosurgery Inc (APEN) Will Post Earnings of -$0.34 Per ShareZacks: Analysts Anticipate Apollo Endosurgery Inc (APEN) Will Post Earnings of -$0.34 Per Share
www.americanbankingnews.com - January 30 at 11:10 PM

SEC Filings

Apollo Endosurgery (NASDAQ:APEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Apollo Endosurgery (NASDAQ:APEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Apollo Endosurgery (NASDAQ APEN) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.